THRD Third Harmonic Bio Inc: רווח נקי למניה ב-12 החודשים האחרונים

Risks for Third Harmonic Bio (THRD) are linked to the clinical trial stage of mast cell inhibitors. However, the GURU.Markets platform reflects the annual percentage change in EPS TTM, where the current mark is 0.00, forming a support level. Stability is provided by diversification within the targeted dermatology segment and the implementation of environmental ESG standards in the development of immunological drugs.
פילוחי מדדים פיננסיים ומדדי שוק עבור Third Harmonic Bio, Inc (THRD)

Year-over-year (YoY) EPS growth (TTM) reflects the dynamics of net income per share compared to the same period last year. This metric is calculated by comparing the total income over the last four quarters with the data from the preceding year. By analyzing YoY TTM net income per share growth, an investor assesses the efficiency of business scaling. For Third Harmonic Bio (THRD), this trend is critical due to fierce competition with pharma behemoths. A steady increase in this indicator would confirm the company's ability to survive the scientific race.